Diplopia, blurred vision and colour disturbances are well-known side effects associated with anti-epileptic drugs (AEDs). Farnsworth-Munsell 100-hue colour test (F-100) is an accepted and sensitive tool to detect changes in colour perception. To determine the impact of AEDs upon colour vision, we evaluated 37 consecutive patients with complex partial seizures exposed to monotherapy with phenytoin (PHT, carbamazepine (CBZ) or valproic acid (VPA). All had normal IQ and no congenital disturbances in colour vision or ocular diseases. Twenty normal controls were used for statistical analysis. Thirteen patients were exposed to PHT, 12 to CBZ and 12 to VPA. Visual colour perception was impaired in 30/37 (82%) of the study group. The most significant abnormality was detected in the blue-yellow axis in 10/13 patients exposed to PHT (p < 0.02) and in 8/12 treated with CBZ (p < 0.009). In 8/12 patients taking VPA, no significant abnormality was observed (p < 0.06). None of the studied patients complained of colour vision disturbances. Our findings strongly support the negative effect of AEDs upon colour vision discrimination, most likely due to changes at the retinal processing level. F-100 proved to be very useful to assess early toxicity due to AEDs.

Keywords:
Colour discrimination, Epileptic patients, Farnsworth-Munsell 100-hue test
1.
Dichter M, Brodie M: New antiepileptic drugs. N Engl J Med 1996;334:1583–1590.
2.
Mattson R, Cramer J, Collins J: Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145–151.
3.
Macdonald RL, Kelly KM: Mechanism of action of currently prescribed and newly developed antiepileptic drugs. Epilepsia 1994;35(suppl 4):S41–S50.
4.
Schmidt D: Adverse Effects of Antiepileptic Drugs. New York, Raven Press, 1982, pp 125–127.
5.
Verriest G, Van Laethem J, Uvijls A: A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores. Am J Ophthalmol 1982;93:635–642.
6.
Smith VC, Pokorny J, Pass A: Color-axis determination on the Farnsworth-Munsell 100-hue test. Am J Ophthalmol 1985;100:176–182.
7.
Büttner Th, Patzld T, Kuhn W, Muller Th, Przuntek H: Impairment of colour discrimination in Parkinson’s disease. Neuroophthalmology 1994;4:91–95.
8.
Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W: Predominant affection of the blue-cone pathway in Parkinson’s disease. Brain 1995;118:771–778.
9.
Hart WM Jr: Acquired dyschromatopsia. Surv Ophthalmol 1987;32:10–31.
10.
Paulus W, Schwarz G, Steinhoff B: The effect of anti-epileptic drugs on visual perception in patients with epilepsy. Brain 1996;119:539–549.
11.
Bayer AU, Thiel J, Zrenner E, Dichgans J, Kuehn M, Paulus W, Ried S, Schmidt D: Color vision test for early detection of antiepileptic drug toxicity. Neurology 1997;48:1394–1397.
12.
Hood DC, Benimoff NL, Greenstein VC: The response range of the blue-cone pathways: A source of vulnerability disease. Invest Ophthalmol Vis Sci 1984;864–867.
13.
Falk G: Retinal physiology; in Heckenlively JR, Arden GB (eds): Principles and Practice of Electrophysiology of Vision. St Louis, Mosby, 1991, pp 69–84.
14.
Wäsle H, Boycott BB: Functional architecture of the mammalian retina. Physiol Rev 1991;71:447–480.
15.
Kolb H: The neural organization in human retina; in Heckenlively JR, Arden GB (eds): Principles and Practice of Clinical Electrophysiology of Vision. St Louis, Mosby, 1991, pp 25–52.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.